Form D · Pharmaceuticals
Moderna LLC
Cambridge, MA · CIK 0001592247
Offering snapshot reported Jan 5, 2015 · SEC filing
- Reported sold
- $446M Offering amount: $502M
- Investors reported
- 43 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 19, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 5, 2015 | Initial | $446,069,409 | No comparison | 43 | SEC filing |
| Jan 23, 2014 | Amendment | $135,000,044 | $25,000,018vs Nov 20, 2013 | 40 | SEC filing |
| Nov 20, 2013 | Initial | $110,000,026 | No comparison | 39 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-231445
Series E Preferred Units
Source: Form D, filed Jan 5, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Noubar Afeyan | Director |
| Lee Babiss | Director |
| Stephane Bancel | Director, Executive |
| Robert Carpenter | Director |
| Peter Hutt | Director |
| James Kasinger | Executive |
| Lorence Kim | Executive |
| Robert Langer | Director |
| Theo Melas Kyriazi | Director |
| John Mendlein | Director |
| Henri Termeer | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
200 Tech Square
Cambridge, MA, 02139
Cambridge, MA, 02139